Skip to nav Skip to content
Brandon  Blue

Brandon Blue, MD

Program: Malignant Hematology

Research Program: Health Outcomes & Behavior Program

Contact

  • Overview

    Associations

    • Malignant Hematology
    • Health Outcomes & Behavior Program

    Education & Training

    Fellowship:

    • Moffitt Cancer Center - Blood and Marrow Transplant and Cellular Immunotherapy
    • Saint Louis University School of Medicine - Hematology/Oncology

    Residency:

    • Washington University School of Medicine - Internal Medicine

    Medical School:

    • Meharry Medical College - MD
  • Research Interest

    Dr. Blue specializes in plasma cell disorders and evaluation and treatment of patients prior to and after stem cell transplantation. Dr. Blue has a research focus in outcomes research. His interest is to explore and eliminate health disparities as it relates to hematologic malignancies.

  • Participating Trials

    Clinical Trial 21858
    A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain AL Amyloidosis
    Condition: Malignant Hematology
    Intervention: Bortezomib (); Daratumumab (Darzalex); Dexamethasone (); Diphenhydramine (); PS-341 (Bortezomib); Velcade (Bortezomib); acetaminophen (); cyclophosphamide (); cytoxan (cyclophosphamide)
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
    • Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: 37855718.
    • Blue B, Pierre A, Mikhael J. Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Sep.23(9):651-659. Pubmedid: 37290997.
    • Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
    • Blue BJ, Brazauskas R, Chen K, Patel J, Hashmi S, Lehmann L, Bhatt N, Wood W, Saber W, Majhail N. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. Transplant Cell Ther. 2023 Nov.29(11):709.e1-709.e11. Pubmedid: 37482244.
    • Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2023 Dec. Pubmedid: 38123069.
    • Bhutani M, Blue BJ, Cole C, Badros AZ, Usmani SZ, Nooka AK, Bernal-Mizrachi L, Mikhael J. Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer J. 2023 Dec.13(1):189. Pubmedid: 38110338. Pmcid: PMC10728116.
    • Blue B, Alomar M, Locke FL. Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative Therapy. JACC CardioOncol. 2023 Dec.5(6):755-757. Pubmedid: 38204996. Pmcid: PMC10774745.
    • Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
    • Peres LC, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton O, Alsina M, Brayer J, Blue B, Baz R, Siqueira Silva A, Nishihori T, Shain KH, Gillis N. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022 Jun.6(12):3767-3778. Pubmedid: 35500227. Pmcid: PMC9631567.
    • Blue B. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transplant Cell Ther. 2022 Jul.28(7):345-346. Pubmedid: 35779944.
    • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
    • Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
    • Fonseca JJ, Yeats AL, Blue B, Zalalutdinov MK, Brintlinger T, Simpkins BS, Ratchford DC, Culbertson JC, Grim JQ, Carter SG, Ishigami M, Stroud RM, Cress CD, Robinson JT. Enabling remote quantum emission in 2D semiconductors via porous metallic networks. Nat Commun. 2020 Jan.11(1):5. Pubmedid: 31911592. Pmcid: PMC6946668.
    • Blue B, Vegunta R, Rodin M, Patolia S, Poddar N. Impact of an Inpatient Palliative Care Consultation in Terminally Ill Cancer Patients. Cureus. 2018 Jul.10(7):e3016. Pubmedid: 30254805. Pmcid: PMC6150761.
    • Blue BJ, Luo S, Sanfilippo KM, Ganti A, Gumbel J, O'Brian K, Carson KR. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. Brit J Haematol. 2017 Jan.176(2):322-324. Pubmedid: 26887893.
    • Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O'Brian K, Carson KR. Statins Are Associated With Reduced Mortality in Multiple Myeloma. J Clin Oncol. 2016 Nov.34(33):4008-4014. Pubmedid: 27646948. Pmcid: PMC5477827.

Find a Researcher Search